Contec Medical Systems Co.,Ltd (SHE:300869)
China · Delayed Price · Currency is CNY 11.22
+0.01 (0.09%)
Sep 4, 2026, 3:04 PM CST
SHE:300869 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 4,504 | 6,027 | 5,601 | 8,289 | 13,087 | 16,293 | |
Market Cap Growth | -33.86% | 7.60% | -32.43% | -36.66% | -19.68% | -65.91% |
Enterprise Value | 3,491 | 4,953 | 5,033 | 7,595 | 12,959 | 16,458 |
Last Close Price | 11.21 | 15.00 | 13.70 | 19.88 | 31.22 | 38.42 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 50.01 | 66.70 | 46.24 |
PS Ratio | 9.46 | 12.88 | 11.67 | 11.10 | 18.38 | 17.93 |
PB Ratio | 2.68 | 3.48 | 3.02 | 4.05 | 6.79 | 8.95 |
P/TBV Ratio | 2.76 | 3.58 | 3.10 | 4.17 | 7.00 | 9.12 |
P/FCF Ratio | - | - | 710.64 | 55.16 | 589.21 | - |
P/OCF Ratio | 150.99 | 270.42 | 89.84 | 45.79 | 126.25 | 3505.79 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.33 | 10.58 | 10.49 | 10.17 | 18.20 | 18.11 |
EV/EBITDA Ratio | - | - | - | 46.91 | 101.63 | 56.68 |
EV/EBIT Ratio | - | - | - | 55.69 | 119.39 | 60.35 |
EV/FCF Ratio | - | - | 638.56 | 50.54 | 583.48 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.51 | 0.56 | 0.42 | 0.51 | 0.82 | 0.44 |
Debt / EBITDA Ratio | - | - | - | 6.40 | 12.20 | 2.77 |
Debt / FCF Ratio | - | - | 99.82 | 6.98 | 70.96 | - |
Net Debt / Equity Ratio | -0.60 | -0.61 | -0.17 | -0.45 | -0.18 | 0.00 |
Net Debt / EBITDA Ratio | 31.88 | 51.58 | 3.73 | -5.65 | -2.74 | -0.03 |
Net Debt / FCF Ratio | 174.74 | 38.94 | -40.74 | -6.09 | -15.74 | 0.10 |
Asset Turnover | 0.18 | 0.17 | 0.16 | 0.22 | 0.22 | 0.37 |
Inventory Turnover | 1.17 | 1.09 | 0.97 | 0.81 | 0.90 | 1.36 |
Quick Ratio | 10.69 | 7.45 | 8.62 | 4.37 | 1.89 | 0.96 |
Current Ratio | 12.22 | 8.39 | 14.25 | 5.40 | 2.30 | 1.42 |
Return on Equity (ROE) | -5.24% | -1.36% | -3.99% | 8.34% | 10.47% | 20.79% |
Return on Assets (ROA) | -1.35% | -1.05% | -2.36% | 2.46% | 2.08% | 6.98% |
Return on Invested Capital (ROIC) | -8.81% | -4.17% | -8.40% | 8.97% | 5.73% | 16.63% |
Return on Capital Employed (ROCE) | -2.40% | -1.90% | -4.30% | 5.00% | 4.10% | 14.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.01% | -0.40% | -1.39% | 2.00% | 1.50% | 2.16% |
FCF Yield | -0.13% | -0.45% | 0.14% | 1.81% | 0.17% | -0.62% |
Dividend Yield | - | - | 1.82% | 1.51% | 0.40% | 0.78% |
Payout Ratio | - | - | - | 41.44% | 63.16% | 29.04% |
Buyback Yield / Dilution | 4.05% | 0.72% | 1.06% | -1.39% | -1.73% | -7.43% |
Total Shareholder Return | 4.05% | 0.72% | 2.89% | 0.12% | -1.33% | -6.64% |